Non-practicing entities have a few characteristics that create an uneven playing field in patent-infringement lawsuits.
Since NPEs aren’t well known and don’t sell anything, they have no need to protect their brand. In many cases they further insulate themselves from negative publicity by using shell companies to bring actions.
When one practicing company sues another for patent infringement, they risk a countersuit – an effective deterrent against filing borderline...
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.
